Tsutomu Hirano

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8071206/publications.pdf

Version: 2024-02-01

109	4,269	87723	128067
papers	citations	38 h-index	60 g-index

111	111	111	4314
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Pathophysiology of Diabetic Dyslipidemia. Journal of Atherosclerosis and Thrombosis, 2018, 25, 771-782.	0.9	271
2	A novel and simple method for quantification of small, dense LDL. Journal of Lipid Research, 2003, 44, 2193-2201.	2.0	171
3	Development of a Homogeneous Assay for Measurement of Small Dense LDL Cholesterol. Clinical Chemistry, 2011, 57, 57-65.	1.5	136
4	Measurement of Small Dense Low-density Lipoprotein Particles. Journal of Atherosclerosis and Thrombosis, 2005, 12, 67-72.	0.9	119
5	Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin. Cardiovascular Diabetology, 2017, 16, 8.	2.7	119
6	Clinical Significance of Small Dense Low-Density Lipoprotein Cholesterol Levels Determined by the Simple Precipitation Method. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 558-563.	1.1	113
7	Counteractive effects of omentin-1 against atherogenesis. Cardiovascular Research, 2016, 110, 118-128.	1.8	113
8	Significance of small dense low-density lipoprotein-cholesterol concentrations in relation to the severity of coronary heart diseases. Atherosclerosis, 2006, 189, 206-214.	0.4	102
9	Human Urotensin II Accelerates Foam Cell Formation in Human Monocyte-Derived Macrophages. Hypertension, 2005, 46, 738-744.	1.3	100
10	A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis. Peptides, 2014, 54, 19-26.	1.2	97
11	Small LDL-Cholesterol is Superior to LDL-Cholesterol for Determining Severe Coronary Atherosclerosis. Journal of Atherosclerosis and Thrombosis, 2008, 15, 250-260.	0.9	80
12	Amelioration of Hyperglycemia with a Sodium-Glucose Cotransporter 2 Inhibitor Prevents Macrophage-Driven Atherosclerosis through Macrophage Foam Cell Formation Suppression in Type 1 and Type 2 Diabetic Mice. PLoS ONE, 2015, 10, e0143396.	1.1	76
13	Elevated Small Dense Low-Density Lipoprotein Cholesterol as a Predictor for Future Cardiovascular Events in Patients with Stable Coronary Artery Disease. Journal of Atherosclerosis and Thrombosis, 2014, 21, 755-767.	0.9	68
14	Remarkably high prevalence of small dense low-density lipoprotein in Japanese men with coronary artery disease, irrespective of the presence of diabetes. Atherosclerosis, 2002, 160, 249-256.	0.4	67
15	Significance of small dense low-density lipoproteins and other risk factors in patients with various types of coronary heart disease. American Heart Journal, 2002, 144, 1026-1035.	1.2	67
16	Preventive Effect of Dipeptidyl Peptidase-4 Inhibitor on Atherosclerosis Is Mainly Attributable to Incretin's Actions in Nondiabetic and Diabetic Apolipoprotein E-Null Mice. PLoS ONE, 2013, 8, e70933.	1.1	65
17	Glucose-Dependent Insulinotropic Polypeptide Prevents the Progression of Macrophage-Driven Atherosclerosis in Diabetic Apolipoprotein E-Null Mice. PLoS ONE, 2012, 7, e35683.	1.1	65
18	Adropin Contributes to Anti-Atherosclerosis by Suppressing Monocyte-Endothelial Cell Adhesion and Smooth Muscle Cell Proliferation. International Journal of Molecular Sciences, 2018, 19, 1293.	1.8	63

#	Article	IF	Citations
19	Preventive Effects of Heregulin-Î² ₁ on Macrophage Foam Cell Formation and Atherosclerosis. Circulation Research, 2009, 105, 500-510.	2.0	61
20	Associations between Small Dense LDL, HDL Subfractions (HDL2, HDL3) and Risk of Atherosclerosis in Japanese-Americans. Journal of Atherosclerosis and Thrombosis, 2012, 19, 444-452.	0.9	59
21	Olmesartan Medoxomil, an Angiotensin II Receptor Blocker Ameliorates Insulin Resistance and Decreases Triglyceride Production in Fructose-Fed Rats. Hypertension Research, 2004, 27, 293-299.	1.5	58
22	Effects of PKF275-055, a dipeptidyl peptidaseâ€“4 inhibitor, on the development of atherosclerotic lesions in apolipoprotein Eâ€“null mice. Metabolism: Clinical and Experimental, 2012, 61, 974-977.	1.5	58
23	Catestatin Prevents Macrophage-Driven Atherosclerosis but Not Arterial Injuryâ€“Induced Neointimal Hyperplasia. Thrombosis and Haemostasis, 2018, 118, 182-194.	1.8	58
24	Lipoprotein lipase mRNA in white adipose tissue but not in skeletal muscle is increased by pioglitazone through PPAR-Î³. Biochemical and Biophysical Research Communications, 2003, 305, 22-27.	1.0	56
25	The Effects of Statin and Fibrate on Lowering Small Dense LDL- Cholesterol in Hyperlipidemic Patients with Type 2 Diabetes. Journal of Atherosclerosis and Thrombosis, 2007, 14, 128-132.	0.9	56
26	Serum Salusin-.ALPHA. Levels Are Decreased and Correlated Negatively with Carotid Atherosclerosis in Essential Hypertensive Patients. Hypertension Research, 2008, 31, 463-468.	1.5	56
27	Chronic infusion of salusin-Î± and -Î² exerts opposite effects on atherosclerotic lesion development in apolipoprotein E-deficient mice. Atherosclerosis, 2010, 212, 70-77.	0.4	56
28	Angiotensin II type 1 receptor blocker ameliorates overproduction and accumulation of triglyceride in the liver of Zucker fatty rats. American Journal of Physiology - Endocrinology and Metabolism, 2004, 287, E227-E232.	1.8	54
29	Very low-density lipoprotein-apoprotein CI is increased in diabetic nephropathy: Comparison with apoprotein CIII. Kidney International, 2003, 63, 2171-2177.	2.6	52
30	Reactions of direct LDL-cholesterol assays with pure LDL fraction and IDL: comparison of three homogeneous methods. Clinica Chimica Acta, 2000, 295, 97-106.	0.5	50
31	Dyslipidemia in diabetes mellitus. Diabetes Research and Clinical Practice, 1996, 33, 1-14.	1.1	48
32	High prevalence of small dense LDL in diabetic nephropathy is not directly associated with kidney damage: a possible role of postprandial lipemia. Atherosclerosis, 1998, 141, 77-85.	0.4	48
33	A simple and precise method for measuring HDL-cholesterol subfractions by a single precipitation followed by homogenous HDL-cholesterol assay. Journal of Lipid Research, 2008, 49, 1130-1136.	2.0	48
34	Lipoprotein abnormalities in diabetic nephropathy. Kidney International, 1999, 56, S22-S24.	2.6	47
35	Remarkable increase of apolipoprotein B48 level in diabetic patients with end-stage renal disease. Atherosclerosis, 2008, 197, 154-158.	0.4	44
36	Abnormal lipoprotein metabolism in diabetic nephropathy. Clinical and Experimental Nephrology, 2014, 18, 206-209.	0.7	44

#	Article	IF	Citations
37	Antiâ€atherogenic and antiâ€inflammatory properties of glucagonâ€like peptideâ€1, glucoseâ€dependent insulinotropic polypepide, and dipeptidyl peptidaseâ€4 inhibitors in experimental animals. Journal of Diabetes Investigation, 2016, 7, 80-86.	1.1	44
38	Role of hepatic lipase in intermediate-density lipoprotein and small, dense low-density lipoprotein formation in hemodialysis patients. Kidney International, 1999, 56, S227-S228.	2.6	43
39	Chronic ANG II infusion increases plasma triglyceride level by stimulating hepatic triglyceride production in rats. American Journal of Physiology - Endocrinology and Metabolism, 2004, 287, E955-E961.	1.8	39
40	The role of endothelial nitric oxide in the anti-restenotic effects of liraglutide in a mouse model of restenosis. Cardiovascular Diabetology, 2017, 16, 122.	2.7	39
41	High prevalence of small LDL particles in non-insulin-dependent diabetic patients with nephropathy. Atherosclerosis, 1996, 123, 57-72.	0.4	38
42	Small Dense Low-Density Lipoprotein in Japanese Men with Coronary Artery Disease. Annals of Internal Medicine, 2000, 132, 762.	2.0	38
43	Neopterin Counters Vascular Inflammation and Atherosclerosis. Journal of the American Heart Association, 2018, 7, .	1.6	38
44	Stimulatory Effects of Cardiotrophin 1 on Atherosclerosis. Hypertension, 2013, 62, 942-950.	1.3	34
45	Method for estimating high sdLDL-C by measuring triglyceride and apolipoprotein B levels. Lipids in Health and Disease, 2017, 16, 21.	1.2	34
46	Measurement of the serum lipoprotein lipase concentration is useful for studying triglyceride metabolism: comparison with postheparin plasma. Metabolism: Clinical and Experimental, 2004, 53, 526-531.	1.5	32
47	No evidence of accelerated atherosclerosis in a 66-yr-old chylomicronemia patient homozygous for the nonsense mutation (Tyr61âţStop) in the lipoprotein lipase gene. Atherosclerosis, 2001, 159, 375-379.	0.4	31
48	Doxazosin reduces prevalence of small dense low density lipoprotein and remnant-like particle cholesterol levels in nondiabetic and diabetic hypertensive patients. American Journal of Hypertension, 2001, 14, 908-913.	1.0	31
49	Increased plasma urotensin-II levels are associated with diabetic retinopathy and carotid atherosclerosis in TypeÂ2 diabetes. Clinical Science, 2008, 115, 327-334.	1.8	31
50	Anagliptin, a dipeptidyl peptidase-4 inhibitor, decreases macrophage infiltration and suppresses atherosclerosis in aortic and coronary arteries in cholesterol-fed rabbits. Metabolism: Clinical and Experimental, 2016, 65, 893-903.	1.5	30
51	Novel phytopeptide osmotin mimics preventive effects of adiponectin on vascular inflammation and atherosclerosis. Metabolism: Clinical and Experimental, 2018, 83, 128-138.	1.5	30
52	Vascular endothelial markers, von willebrand factor and thrombomodulin index, are specifically elevated in type 2 diabetic patients with nephropathy: comparison of primary renal disease. Clinica Chimica Acta, 2000, 299, 65-75.	0.5	29
53	Intensive insulin therapy reduces small dense low-density lipoprotein particles in patients with type 2 diabetes mellitus: relationship to triglyceride-rich lipoprotein subspecies. Metabolism: Clinical and Experimental, 2006, 55, 879-884.	1.5	29
54	Effects of Statin on Small Dense Low-Density Lipoprotein Cholesterol and Remnant-Like Particle Cholesterol in Heterozygous Familial Hypercholesterolemia. Journal of Atherosclerosis and Thrombosis, 2008, 15, 146-153.	0.9	29

#	Article	IF	Citations
55	High-Density Lipoprotein Subfractions and Their Oxidized Subfraction Particles in Patients with Chronic Kidney Disease. Journal of Atherosclerosis and Thrombosis, 2016, 23, 81-94.	0.9	29
56	GIP as a Potential Therapeutic Target for Atherosclerotic Cardiovascular Diseaseâ€"A Systematic Review. International Journal of Molecular Sciences, 2020, 21, 1509.	1.8	29
57	Chemerin-9, a potent agonist of chemerin receptor (ChemR23), prevents atherogenesis. Clinical Science, 2019, 133, 1779-1796.	1.8	29
58	Treatment of Small Dense LDL. Journal of Atherosclerosis and Thrombosis, 2002, 9, 266-275.	0.9	28
59	Chronic urotensin II infusion enhances macrophage foam cell formation and atherosclerosis in apolipoprotein E-knockout mice. Journal of Hypertension, 2008, 26, 1955-1965.	0.3	27
60	A Dipeptidyl Peptidase-4 Inhibitor but not Incretins Suppresses Abdominal Aortic Aneurysms in Angiotensin II-Infused Apolipoprotein E-Null Mice. Journal of Atherosclerosis and Thrombosis, 2016, 23, 441-454.	0.9	27
61	Atheroprotective Effects of TumorÂNecrosis Factorâ€"Stimulated Gene-6. JACC Basic To Translational Science, 2016, 1, 494-509.	1.9	27
62	Potent Vasoconstrictor Kisspeptinâ€10 Induces Atherosclerotic Plaque Progression and Instability: Reversal by its Receptor GPR54 Antagonist. Journal of the American Heart Association, 2017, 6, .	1.6	27
63	Decreased peroxisome proliferatorâ€"activated receptor Î± gene expression is associated with dyslipidemia in a rat model of chronic renal failure. Metabolism: Clinical and Experimental, 2007, 56, 1714-1718.	1.5	26
64	Anti-Atherogenic Effects of Vaspin on Human Aortic Smooth Muscle Cell/Macrophage Responses and Hyperlipidemic Mouse Plaque Phenotype. International Journal of Molecular Sciences, 2018, 19, 1732.	1.8	26
65	Caveolin-1, a binding protein of CD26, is essential for the anti-inflammatory effects of dipeptidyl peptidase-4 inhibitors on human and mouse macrophages. Biochemical and Biophysical Research Communications, 2018, 495, 223-229.	1.0	25
66	Endogenous Bioactive Peptides as Potential Biomarkers for Atherosclerotic Coronary Heart Disease. Sensors, 2012, 12, 4974-4985.	2.1	23
67	Vasoprotective Effects of Urocortin 1 against Atherosclerosis In Vitro and In Vivo. PLoS ONE, 2014, 9, e110866.	1.1	21
68	Development of a homogeneous assay for measurement of high-density lipoprotein-subclass cholesterol. Clinica Chimica Acta, 2014, 427, 86-93.	0.5	21
69	Effect of Ezetimibe on LDL-C Lowering and Atherogenic Lipoprotein Profiles in Type 2 Diabetic Patients Poorly Controlled by Statins. PLoS ONE, 2015, 10, e0138332.	1.1	21
70	Glucose-Dependent Insulinotropic Polypeptide Suppresses Peripheral Arterial Remodeling in Male Mice. Endocrinology, 2018, 159, 2717-2732.	1.4	21
71	A Dipeptidyl Peptidase-4 Inhibitor Inhibits Foam Cell Formation of Macrophages in Type 1 Diabetes via Suppression of CD36 and ACAT-1 Expression. International Journal of Molecular Sciences, 2020, 21, 4811.	1.8	20
72	Inhibitory effects of vasostatin-1 against atherogenesis. Clinical Science, 2018, 132, 2493-2507.	1.8	19

#	Article	IF	Citations
73	Legumain Promotes Atherosclerotic Vascular Remodeling. International Journal of Molecular Sciences, 2019, 20, 2195.	1.8	18
74	Dyslipidemia in diabetic kidney disease classified by proteinuria and renal dysfunction: A crossâ€sectional study from a regional diabetes cohort. Journal of Diabetes Investigation, 2022, 13, 657-667.	1.1	18
75	Association Between Small Dense Low-Density Lipoprotein and Postprandial Accumulation of Triglyceride-Rich Remnant-Like Particles in Normotriglyceridemic Patients With Myocardial Infarction. Circulation Journal, 2004, 68, 1165-1172.	0.7	17
76	Angiotensin II infusion increases hepatic triglyceride production via its type 2 receptor in rats. Journal of Hypertension, 2005, 23, 1525-1530.	0.3	17
77	Antiatherogenic effects of liraglutide in hyperglycemic apolipoprotein E-null mice via AMP-activated protein kinase-independent mechanisms. American Journal of Physiology - Endocrinology and Metabolism, 2019, 316, E895-E907.	1.8	17
78	Lipocalin-2 exerts pro-atherosclerotic effects as evidenced by in vitro and in vivo experiments. Heart and Vessels, 2020, 35, 1012-1024.	0.5	17
79	Intracellular apoprotein B degradation is suppressed by decreased albumin concentration in Hep G2 cells. Kidney International, 1995, 47, 421-431.	2.6	16
80	Opposing actions of angiotensin II type 1 and 2 receptors on plasma cholesterol levels in rats. Journal of Hypertension, 2006, 24, 103-108.	0.3	16
81	A new device for foot sensory examination employing auto-presentation of shear force stimuli against the skin. Journal of Biomechanical Science and Engineering, 2015, 10, 14-00487-14-00487.	0.1	16
82	Effect of Dulaglutide Versus Liraglutide on Glucose Variability, Oxidative Stress, and Endothelial Function in Type 2 Diabetes: A Prospective Study. Diabetes Therapy, 2019, 10, 215-228.	1.2	16
83	High-density lipoprotein subspecies between patients with type 1 diabetes and type 2 diabetes without / with intensive insulin therapy. Endocrine Journal, 2012, 59, 561-569.	0.7	14
84	Long-term efficacy of bezafibrate in reduction of small, dense low-density lipoprotein by hypotriglyceridemic action. Current Therapeutic Research, 2000, 61, 127-136.	0.5	12
85	Circadian rhythm of serum concentration of small dense low-density lipoprotein cholesterol. Clinica Chimica Acta, 2007, 376, 96-100.	0.5	12
86	Serum concentration of small dense low-density lipoprotein-cholesterol during oral glucose tolerance test and oral fat tolerance test. Clinica Chimica Acta, 2008, 387, 36-41.	0.5	11
87	Metabolic Properties of Lowdensity Lipoprotein (LDL) Triglycerides in Patients with Type 2 Diabetes, Comparison with Small Dense LDL-Cholesterol. Journal of Atherosclerosis and Thrombosis, 2022, 29, 762-774.	0.9	11
88	Marked decrease of apolipoprotein A-V in both diabetic and nondiabetic patients with end-stage renal disease. Metabolism: Clinical and Experimental, 2007, 56, 462-463.	1.5	10
89	Small dense LDL-cholesterol determined by a simple precipitation assay for screening familial combined hyperlipidemia. Atherosclerosis, 2009, 205, 603-607.	0.4	10
90	Comparison of liraglutide plus basal insulin and basal-bolus insulin therapy (BBIT) for glycemic control, body weight stability, and treatment satisfaction in patients treated using BBIT for type 2 diabetes without severe insulin deficiency: A randomized prospective pilot study. Diabetes Research and Clinical Practice, 2018, 140, 339-346.	1.1	10

#	Article	IF	Citations
91	Teneligliptin, a Dipeptidyl Peptidase-4 Inhibitor, Improves Early-Phase Insulin Secretion in Drug-NaÃ¯ve Patients with Type 2 Diabetes. Drugs in R and D, 2015, 15, 245-251.	1.1	9
92	Serum CETP status is independently associated with reduction rates in LDL-C in pitavastatin-treated diabetic patients and possible involvement of LXR in its association. Lipids in Health and Disease, 2016, 15, 57.	1.2	9
93	Combination Therapy with a Sodium-Glucose Cotransporter 2 Inhibitor and a Dipeptidyl Peptidase-4 Inhibitor Additively Suppresses Macrophage Foam Cell Formation and Atherosclerosis in Diabetic Mice. International Journal of Endocrinology, 2017, 2017, 1-9.	0.6	9
94	A Dipeptidyl Peptidase-4 Inhibitor Suppresses Macrophage Foam Cell Formation in Diabetic db/db Mice and Type 2 Diabetes Patients. International Journal of Endocrinology, 2018, 2018, 1-9.	0.6	9
95	Î²-Endorphin Mediates the Development and Instability of Atherosclerotic Plaques. International Journal of Endocrinology, 2020, 2020, 1-11.	0.6	8
96	Smaller lowâ€density lipoprotein size as a possible risk factor for the prevalence of coronary artery diseases in haemodialysis patients: Associations of cholesteryl ester transfer protein and the hepatic lipase gene polymorphism with lowâ€density lipoprotein size. Nephrology, 2011, 16, 558-566.	0.7	7
97	Increment of C-peptide after glucagon injection determines the progressive nature of Japanese type 2 diabetes: A long-term follow-up study. Endocrine Journal, 2013, 60, 715-724.	0.7	7
98	Increased detection of mild cognitive impairment with type 2 diabetes mellitus using the Japanese version of the Montreal Cognitive Assessment: A pilot study. Neurology and Clinical Neuroscience, 2015, 3, 89-93.	0.2	7
99	Glucose-Dependent Insulinotropic Polypeptide Suppresses Foam Cell Formation of Macrophages through Inhibition of the Cyclin-Dependent Kinase 5-CD36 Pathway. Biomedicines, 2021, 9, 832.	1.4	7
100	Nesfatin-1 suppresses peripheral arterial remodeling without elevating blood pressure in mice. Endocrine Connections, 2019, 8, 536-546.	0.8	6
101	Circadian Rhythm of Subspecies of Low-Density Lipoprotein-Cholesterol and High-Density Lipoprotein-Cholesterol in Healthy Subjects and Patients with Type 2 Diabetes. Journal of Atherosclerosis and Thrombosis, 2023, 30, 3-14.	0.9	5
102	The effect of exogenous arachidonic acid on insulin secretion in isolated perifused hamster islets.. Endocrinologia Japonica, 1984, 31, 549-555.	0.5	4
103	RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL-C Goal), a randomized, doctor-oriented, multicenter trial to compare the effects of higher-dose statin versus ezetimibe-plus-statin on the serum LDL-C concentration of Japanese type-2 diabetes patients design and rationale. Lipids in Health and Disease, 2013, 12, 142.	1.2	4
104	A higher body mass index attenuates the long-term HbA1c-lowering effects of liraglutide in type 2 diabetes patients treated using sulfonylurea-based therapy. Diabetology International, 2016, 7, 425-431.	0.7	1
105	Effect of simvastatin on apoprotein Bâ€"containing lipoproteins in patients with diabetic nephropathy. Current Therapeutic Research, 2002, 63, 33-42.	0.5	0
106	SP617OXIDIZED HDL INFLUENCES PREDICTIVE ABILITY OF APOLIPOPROTEIN A2 TO CVD EVENTS IN HEMODIALYSIS PATIENTS. Nephrology Dialysis Transplantation, 2016, 31, i301-i301.	0.4	0
107	Protective Effect of Anti-diabetic Drugs on Cardiovascular Diseases. The Journal of the Japanese Society of Internal Medicine, 2017, 106, 1029-1036.	0.0	0
108	Involvement of Vascular Endothelial Cells in the Anti-atherogenic Effects of Liraglutide in Diabetic Apolipoprotein E-null Mice. The Showa University Journal of Medical Sciences, 2019, 31, 115-124.	0.1	0

#	Article	IF	Citations
109	Significance of Small Dense Low-Density Lipoproteins in Coronary Heart Disease. , 2008, , 115-123.		0